Terumo Revises Interim Dividend Distribution and Year-End Dividends Forecast for Fiscal Year Ending March 31, 2022
November 04, 2021 at 02:32 am EDT
Share
November 4, 2021
Terumo Revises Interim Dividend Distribution and Year-End Dividends
Forecast for Fiscal Year Ending March 31, 2022
TOKYO, JAPAN - November 4, 2021 - Terumo Corporation (TSE: 4543) decided at the Board of Directors meeting held on November 4, 2021 to distribute retained earnings as of September 30, 2021. Both the interim dividends and the dividends forecast per share for fiscal year ending March 31, 2022 will be revised upwards as described below.
1. Details of interim dividends
Decided Dividends
Previous Forecast
FY2020 Interim
(As of May 12, 2021)
Dividends
Date of Record
September 30, 2021
September 30, 2021
September 30, 2020
Dividends per
16.00 JPY
15.00 JPY
14.00 JPY
Share
Total Amount of
12.1 billion JPY
10.6 billion JPY
Dividends
Effective Payout
December 3, 2021
December 2, 2020
Date
Source of
Retained earnings
Retained earnings
Dividends
2. Details of the revision
Dividends per Share
End of Second
End of Fiscal Year
Annual
Quarter
Previous Forecast
15.00
JPY
15.00 JPY
30.00 JPY
Revised Forecast
16.00 JPY
32.00 JPY
FY2021 Actual
(ending March 31,
16.00
JPY
2022)
FY2020 Actual
(ended March 31,
14.00
JPY
15.00 JPY
29.00 JPY
2021)
(Reference) FY2021 Guidance: Profit attributable to owners of parent = 92 billion JPY
3. Reason of revision
As a measure to secure high profit margins and sustainable growth, Terumo is committed to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo will aim to steadily increase its dividend payouts to shareholders and has set a mid to long- term dividend payout ratio target of 30%.
Based on the above policy and recent financial results, the company decided to increase the interim dividend distribution to 16.00 JPY and year-end dividends to 16.00 JPY per share.
Disclaimer
Among the information that Terumo discloses, the forward-looking statements contain potential risks and uncertainty since these are made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results might differ from those statements due to various factors.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Attachments
Original document
Permalink
Disclaimer
Terumo Corporation published this content on 04 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 06:31:06 UTC.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).